Health News Releases

  • Today December 20
October 15, 2018 13:45
Chugai Releases Disease Awareness Anime about Rheumatoid Arthritis in Multiple Languages Emphasizing Importance of Early Detection/Treatment and Care by Specialists
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that it released a disease awareness anime about rheumatoid arthritis dubbed in English and subtitled in Chinese, Korean, French and Spanis
October 11, 2018 15:50
New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018
Celgene Corporation (NASDAQ:CELG) today announced the results of two post hoc analyses of data from the phase 3 SUNBEAM™ and RADIANCE™ Part B trials, which evaluated the efficacy and safety of ozanimo
October 09, 2018 10:35
Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint
Celgene Corporation (NASDAQ:CELG) today announced results from the phase 3 STYLE study, which showed that OTEZLA® (apremilast) 30 mg twice daily achieved a highly statistically significant improvement
October 07, 2018 17:35
Brightree Launches BrightreeCARE App for Home Health and Hospice Aides
Brightree®, the leading provider of cloud-based software to help post-acute care companies improve business performance and patient outcomes, announced today the release of its new BrightreeCARE app.
October 05, 2018 19:40
Life Biosciences Acquires Lua, Pioneering AI-Driven Healthcare Platform
Life Biosciences today announced it is acquiring Lua, the communication and technology platform. This bold step is intended to facilitate the creation of a proprietary artificial intelligence (AI) pla
October 05, 2018 13:50
Boehringer Ingelheim and Lilly present full results of Trajenta®’s CARMELINA® cardiovascular outcome trial
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linaglipti
October 04, 2018 17:25
PharmAbcine Announces FDA Accepts IND Application of TTAC-0001 for the Treatment of Recurrent Glioblastoma
PharmAbcine, Inc, a clinical-stage biotech company developing novel antibody therapeutics for multiple cancer indications announces that the company received “Study May Proceed Letter “ from the US Fo
October 02, 2018 20:00
Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint. The trial demonstrated a s
October 02, 2018 14:25
New Study Evaluates the Ability of Masimo ORi™ to Help Clinicians Reduce Hyperoxemia in Mechanically Ventilated ICU Patients
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Congress of the French Society of Anesthesia and Resuscitation (SFAR) in Paris in which researchers at CHU Anger
October 01, 2018 00:35
Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders
Further to the announcement of the recommended acquisition of Shire plc (“Shire”) on May 8, 2018 (“the Acquisition”), Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda” or the “Company”) toda
September 28, 2018 15:20
Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial, demonstrating that ALUNBRIG reduced the r
September 27, 2018 14:00
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequ
September 26, 2018 18:25
WIPO and IFPMA Launch New Online Patent-Search Resource to Help Health Agencies Procure Medicines
WIPO and the research-based pharmaceutical industry today launched a new online tool designed to help procurement agencies better understand the global patent status of medicines. The Patent Inform
September 25, 2018 19:25
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recom
September 19, 2018 16:00
175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis
Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading
September 19, 2018 09:00
Aspect Biosystems Announces Liver Tissue Collaboration with JSR
Aspect Biosystems, a privately held biotechnology company focused on commercializing cutting-edge bioprinting technologies, is pleased to announce a new collaboration to develop human liver tissue wit
September 18, 2018 15:55
THE NUVISAN GROUP Continues Its Growth by Adding Parts of the GALDERMA R&D Capabilities from NESTLÉ SKIN HEALTH
On August 31st the NUVISAN GROUP, one of Europe´s leading CRO´s focused on early stage drug development for the life science industry, signed an agreement with NESTLÉ SKIN HEALTH/ GALDERMA to take ove
September 17, 2018 22:05
MEDTEX: Foresee the Next Wave of Healthcare Revolution
Taiwan, with high quality medical service and world’s top IT industry, has becoming one of the leaders in global healthcare technology and provider. On November 29 - 30, MEDTEX will focus on 3 key tre
September 17, 2018 18:15
Large European real-world study reports effects of Spiolto® Respimat® for people living with COPD in daily clinical practice[1]
For media excluding the United States of America, Canada and the United Kingdom Boehringer Ingelheim announced results from the OTIVACTO study, an observational European real-world study of 7,443 C
September 17, 2018 10:15
Clinical trial data for nintedanib in patients with advanced IPF published
Results from the INSTAGE® trial have been presented at the 2018 European Respiratory Society (ERS) conference in Paris and published in the New England Journal of Medicine.[1] The trial reports clinic
September 17, 2018 10:05
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
Results from INPULSIS®-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy and tolerability of Ofev® (nintedanib) in patients with idiopathic pulmo
September 14, 2018 16:00
ResMed Introduces Its First Minimal-contact Full Face CPAP Mask, AirFit F30
ResMed (NYSE: RMD) (ASX: RMD) today introduced its first minimal-contact full face CPAP mask, AirFit F30, the latest addition to its AirFit mask portfolio, which helps users reduce facial marks, wear
September 14, 2018 15:00
Acelity Enters Agreement to Transition Systagenix Manufacturing Facility to Scapa Healthcare
Today, Acelity announced an agreement to sell its advanced wound dressings manufacturing facility located in Gargrave, England, to Scapa Healthcare. In conjunction with the transfer of the facility up
September 13, 2018 18:25
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Boehringer Ingelheim today announced that it has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies. ViraTherapeutics dev
September 13, 2018 17:30
OptraSCAN® Receives CE Mark Approval for In-Vitro Diagnostics Use
OptraSCAN®, the leading end-to-end digital pathology solution provider, today announced that their whole-slide scanners have received CE Mark approval for European Standards applicable to “In-Vitro Di
25 per page50 per page75 per page100 per page